ArticleVaccines2025

Nirsevimab Prophylaxis for Reduction of Respiratory Syncytial Virus Complications in Hospitalised Infants: The Multi-Centre Study During the 2023-2024 Season in Andalusia, Spain (NIRSEGRAND).

David Moreno-Pérez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.